| Severity* | Frequency of general symptoms | Frequency of nighttime symptoms | Flare-ups (exacerba- tions)** |
|---|---|---|---|
| Mild intermittent | Twice a week or less | Twice a month or less | Brief (a few hours to a few days) with varying intensity |
| Mild persistent | Twice a week or more but less than once a day | More than twice a month | May be severe enough to restrict physical activity |
| Moderate persistent | Daily, often accompanied by daily use of rescue inhaler | More than once a week | Twice a week or more, possibly severe enough to restrict physical activity |
| Severe persistent | Continual, with limited physical activity | Frequent | Frequent |
| Level of severity | Forced expiratory volume (FEV-1) or Peak expiratory flow=20 (PEF) | Peak expiratory flow (PEF) variability |
|---|---|---|
| Mild intermittent | At least 80% | Less than 20% |
| Mild persistent | At least 80% | 20% - 30% |
| Moderate persistent | 60% - 80% | Greater than 30% |
| Severe persistent | 60% or less | Greater than 30% |
| Level of severity | Treatment for long-term control | |||
|---|---|---|---|---|
| Age 6 through adult | Age 5 and under | |||
| Preferred method | Alternative method | Preferred method | Alternative method | |
| Mild intermittent | No daily medication; for severe attacks, oral, injected or intravenous cortico- steroids recom- mended |
None | No daily medication; for severe attacks, oral, injected or intravenous cortico- steroids recom- mended |
None |
| Mild persistent | Low-dose inhaled cortico- steroids |
Cromolyn, leukotriene modifier, nedocromil, or sustained-release theophylline | Low-dose inhaled cortico- steroids |
Leukotriene modifier or cromolyn |
| Moderate persistent | Low- to medium-dose inhaled cortico- steroids and long-acting beta-2 agonists |
Low- to medium-dose inhaled cortico- steroids and either leukotriene modifier or theophylline |
Low-dose inhaled cortico- steroids and long-acting beta-2 agonists, or medium-dose inhaled cortico- steroids |
Low- to medium-dose inhaled cortico- steroids and either leukotriene modifier or theophylline |
| Severe persistent | High-dose inhaled cortico- steroids and long-acting beta-2 agonists plus (if needed) oral cortico- steroids |
None | High-dose inhaled cortico- steroids and long-acting beta-2 agonists plus (if needed) oral cortico- steroids |
None |
